Annual Report 2002 - Roche

More documents

Recommendations

Info

R698 (T-20)/Fuzeon 15) fusion inhibitor (enfuvirtide) HIV infection R724 (T-1249) 15) fusion inhibitor HIV infection R1270/Levovirin 13) new generation nucleoside analogue (levovirin) hepatitis C Fortovase protease inhibitor (saquinavir) pediatric formulation Pegasys pegylated interferon (peginterferon alfa-2a) chronic hepatitis B Viracept 16) protease inhibitor (nelfinavir mesylate) HIV infection, new formulation Participation through Genentech b) MLN-02 antibody (former LDP-02 antibody) monoclonal antibody inflammatory bowel disease TF Fab monoclonal antibody fragment acute coronary syndrome Avastin anti-VEGF antibody (avastin) solid tumours with chemotherapy AMD fab monoclonal antibody fragment age-related macular degeneration Raptiva (formally Xanelim) anti-CD11a antibody (efalizumab) psoriasis rheumatoid arthritis Xolair anti-IgE antibody (omalizumab) asthma Participation through Chugai b) AHM monoclonal antibody multiple myeloma CHS13340 recombinant parathyroid hormone osteoporosis CHC12103 polyglutamate TXL breast cancer CAL monoclonal antibody bone metastases ED-71 vitamin D derivative osteoporosis BO-653 anti-oxidant coronary heart disease GM-611 motilin agonist gastroparesis VAL liver regenerator post hepatectomy Antevas subarachnoid hemorrhage MRA monoclonal antibody rheumatoid arthritis Evista 17) (raloxifene HCl) osteoporosis in postmenopausal women Renagel 18) (sevelamer HCl) hyperphosphatemia Femara 19) (letrozole) breast cancer in postmenopausal women Opt-in opportunities c) Antisoma (DMXAA) vascular targeting agent solid tumours TheraFab monoclonal antibody fragment non-small cell lung cancer Axovan AXV034343 endothelin A receptor antagonist subarachnoid hemorrhage Basilea Pharmaceutica (BAL2299) nuclear receptor modulator psoriasis (BAL4079) 9-cis retinoic acid chronic hand eczema (BAL5788) antibiotic bacterial infection (BAL8349) antifungal fungal infection (BAL8557) antifungal fungal infection Speedel R639 (SPP301) endothelin A receptor antagonist cardiovascular disease External partners: 1) Gryphon Sciences 2) Genetics Institute 3) GlaxoSmithKline 4) Genentech/IDEC 5) Memory Pharmaceuticals 6) Kosan Biosciences 7) Genentech 8) Antisoma 9) Beaufour Ipsen 10) Genentech/OSI 11) Isotechnika 12) Medivir 13) ICN 14) Stressgen 15) Trimeris 16) Agouron 17) Eli Lilly 18) Genzyme/Kirin Brewery 19) Novartis a) For competitive reasons, some projects may not have been identified. b) Full consolidation. c) <strong>Roche</strong> retains the right to license the product. Blue type represents new molecular entities (NMEs). Current as of 31 January 2003. There are currently 65 NMEs in the Pharmaceuticals Division’s development pipeline. Of these, 19 are in early-stage development (phase 0), 14 have entered phase I clinical testing, 24 are in phase II, and 8 in phase III/filed. Phase 0: Transition from preclinical to clinical development Phase I: Initial studies in healthy volunteers Phase II: Small-scale efficacy, tolerability and dose-finding studies in patients Phase III: Large-scale studies in patients for statistical confirmation of safety and efficacy
oncology portfolio, the roll-out of Pegasys and Fuzeon and the integration of Chugai expected to fuel solid double-digit growth. We anticipate that the synergies resulting from the integration of Chugai will take full effect in 2004. The division remains committed to raising its operating profit margin towards 25% in the next two years. Pharmaceuticals 31
Page 1 and 2: Annual Report 2002 Roche Group Annu
Page 3 and 4: Group Performance at a Glance Sales
Page 5 and 6: Roche Group Annual Report and Group
Page 7 and 8: The sale of the Vitamins and Fine C
Page 9 and 10: While continuing with the successfu
Page 11 and 12: in biotechnology. At the beginning
Page 13 and 14: emain stable. Given the volatility
Page 15 and 16: Board of Directors as of 1 January
Page 17 and 18: Executive Committee from 1 January
Page 19 and 20: persons closely associated with the
Page 21 and 22: usinesses through targeted acquisit
Page 23 and 24: Pharmaceuticals Division in brief c
Page 25 and 26: also posted double-digit gains. Alt
Page 27 and 28: Western Europe. In November this no
Page 29 and 30: Transplantation - strong growth for
Page 31 and 32: ing positive decisions on both fili
Page 33 and 34: Research and development - substant
Page 35: Substantially expanded pipeline Ind
Page 39 and 40: Diagnostics Division in brief chang
Page 41 and 42: Helping to shape the future. Roche
Page 43 and 44: thing from glucose self-monitoring
Page 45 and 46: Centralized Diagnostics. Sales by o
Page 47 and 48: The global roll-out of Cobas TaqMan
Page 49 and 50: Vitamins and Fine Chemicals Divisio
Page 51 and 52: division outperformed expectations
Page 53 and 54: People and the Environment Human re
Page 55 and 56: worldwide the opportunity to purcha
Page 57 and 58: Safety and Environmental Protection
Page 59 and 60: Social Involvement The many faces o
Page 61 and 62: ‘We do not intend to make a profi
Page 63 and 64: Financial Review Figures reported F
Page 65 and 66: Treasury and Financing During 2002
Page 67 and 68: Operating profit: Double-digit incr
Page 69 and 70: Pharmaceuticals: Operating profit a
Page 71 and 72: Net income in millions of CHF On a
Page 73 and 74: Foreign currency translation effect
Page 75 and 76: The adjusted basis The concept of t
Page 77 and 78: in millions of CHF Reconciliation o
Page 79 and 80: Consolidated balance sheet in milli
Page 81 and 82: Consolidated cash flow statement in
Page 83 and 84: Foreign currency translation Most G
Page 85 and 86: Deferred income tax is provided, us
Page 87 and 88:
Provisions Provisions are recognise
Page 89 and 90:
Changes effective 1 January 2001 Se
Page 91 and 92:
Liquidity risk Group companies need
Page 93 and 94:
Total Core Vitamines and Pharmaceut
Page 95 and 96:
of which the Group’s majority int
Page 97 and 98:
6. Chugai On 10 December 2001, Roch
Page 99 and 100:
The fair value adjustments to inven
Page 101 and 102:
Vitamin case Following the settleme
Page 103 and 104:
10. Employee benefits in millions o
Page 105 and 106:
The Group operates defined benefit
Page 107 and 108:
12. Financial income (expense), net
Page 109 and 110:
Income tax assets and liabilities A
Page 111 and 112:
Patents, licences, trademarks 2002
Page 113 and 114:
18. Other long-term assets in milli
Page 115 and 116:
25. Equity Share capital At the Ann
Page 117 and 118:
28. Minority interests in millions
Page 119 and 120:
The carrying value of the Group’s
Page 121 and 122:
2002 2001 Foreign currency derivati
Page 123 and 124:
33. Cash flow statement in millions
Page 125 and 126:
Report of the Group Auditors To the
Page 127 and 128:
1995 1996 1997 c) 1998 1999 2000 20
Page 129 and 130:
Additions to property, plant and eq
Page 131 and 132:
Number of shares and non-voting equ
Page 133 and 134:
Outstanding issues Summarised issue
Page 135 and 136:
Balance sheet at 31 December in mil
Page 137 and 138:
Participations The major participat
Page 139 and 140:
Report of the Statutory Auditors To
Page 141 and 142:
120° 30° 150° 90° 60° 30° 0°
Page 143 and 144:
Garden City, 70.000 GBP | Roche Reg
Page 145 and 146:
Diagnostics 27% Sales by division 1
show all

Annual Report 2002 - Roche

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?